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Abstract
Aim and methods: We prospectively investigated whether early diagnosis of amyotrophic lateral sclerosis (ALS) could be facilitated by
demonstrating signs of denervation in a muscle of a clinical and electromyographical unaffected region. Muscle fibre conduction velocity
(MFCV) was determined in 18 patients in whom the diagnosis ALS was considered but not established beyond a level of clinically possible
ALS according to the revised El Escorial criteria. A muscle biopsy was obtained from the same muscle, to demonstrate neurogenic changes.
The study followed the guidelines from the STARD initiative.
Results and conclusion: Results were analysed with respect to the final diagnosis. After a mean follow-up of 16 months, 9 patients developed
probable or definite ALS. Sensitivity of abnormal MFCV for developing ALS was 89%. Muscle biopsy confirmed that denervation was the
cause of abnormal MFCV. We concluded that MFCV can be used to detect denervation in muscles that show no clinical or
electromyographical signs of lower motor neuron disease, and thus may contribute to early diagnosis of probable laboratory-supported ALS.
© 2007 Elsevier B.V. All rights reserved.
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1. Introduction
Needle electromyography (nEMG) can be an important
contributor to early diagnosis of amyotrophic lateral sclerosis
(ALS). Fibrillation potentials, positive waves, and abnormal
motor unit potentials may indicate lower motor neuron (LMN)
dysfunction prior to weakness or muscle atrophy [1,2].
According to the revised El Escorial criteria, such findings
may lift the diagnosis from clinically possible ALS to clini-
cally probably laboratory-supported ALS [3]. A clear
definition of the stage of the disease is desirable for good
clinical practice, and mandatory for research purposes.
Nevertheless, in some patients with clinical signs or symptoms
of possible ALS, evidence for LMN or upper motor neuron
(UMN) disease in other regions cannot be found. These
patients are faced with a period of uncertainty, because a
diagnosis of ALS, or any other disorder, is usually only
established after time has elapsed. In some of these patients,
there is a need for a diagnostic technique that is capable of
detecting changes in muscle tissue due to LMN disease, even
before needle EMG can. Measurement of muscle fibre
conduction velocity (MFCV)may be such an EMG technique.
Increased fibre diameter variability can be an early sign of
denervation [4], MFCV is related to fibre diameter in a linear
fashion [5] and abnormal MFCVin muscles affected by motor
neuron degeneration has been reported before [6].
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In the present study, we prospectively estimated the
diagnostic accuracy of MFCV in patients with possible ALS,
or unexplained LMN symptoms. Measurements were made
in a region that was clinically unaffected, and showed no
nEMG signs of denervation. Muscle biopsies were obtained
from the same muscle to verify the origin of abnormal
findings. This study used the guidelines from the STARD
initiative for studies on diagnostic techniques [7].
2. Methods
Patients were recruited from the Neuromuscular Centre
Nijmegen, which is a secondary referral centre for patients
with motor neuron disease. During a study period of 3 years,
patients were consecutively included if they fulfilled the
revised El Escorial (Airlie House) criteria of possible ALS,
or if the underlying cause of LMN dysfunction in one or two
regions could not be identified and ALS was considered.
Clinically possible ALS was defined when clinical signs of
UMN and LMN dysfunction were found together in only one
region, or UMN signs were found alone in two or more
regions; or LMN signs were found rostral to UMN signs and
the diagnosis of clinically probable laboratory-supported
ALS could not be proven by evidence on clinical grounds in
conjunction with neurophysiologic, neuroimaging or clinical
laboratory studies. Patients with a pure LMN syndrome in
one or two regions were included if progressive muscle
atrophy was present in at least 2 muscles, muscles not in-
nervated by the same nerve or root, and in whom a diagnosis
could not be established on clinical grounds in conjunction
with neurophysiologic and neuroimaging studies.
Approximately 250 ALS patients were seen during the
study period, and approximately 7% of these met the
inclusion criteria of this study. Informed consent was asked
before inclusion, and the study was carried out according to
the Helsinki Principles.
Prior to inclusion, diagnostic needle EMG was performed
according to established principles, by an experienced neuro-
physiologist. In the region that was to be studied, spontane-
ous muscle fibre discharges were absent, and motor unit
potentials and interference pattern characteristics were within
normal limits.
MFCV was obtained from a proximal muscle in a region
that was clinically unaffected, and showed no evidence of
LMN disease by nEMG examination. Thus, the quadriceps
muscle was examined if the patient had UMN or LMN signs
in an upper extremity, while the brachial biceps muscle was
examined if the patient had UMN or LMN signs in a lower
extremity. MFCV measurements were performed by the first
author, who had not participated in the clinical and EMG
examination prior to inclusion. MFCV was measured using a
modified invasive technique [8,9]. Needle electrodes were
used to evoke and record muscle fibre potentials. At least 25
muscle fibre potentials were recorded in each patient, which
usually took about 15 min. Mean MFCV was calculated
using all fibres measured, and the ratio of slowest to fastest
velocities (F/S ratio) was used to indicate scatter of veloc-
ities. A test was considered abnormal if either mean MFCV,
or F/S ratio, or both were abnormal. Normal values of our
control population have been reported before (mean MFCV,
3.6 m/s; standard deviation (SD), 0.4 m/s; F/S ratio, 1.5; SD,
0.3 m/s) [8]. Cutoff values were set at 2 SD below normal for
mean MFCV (N2.8 m/s), and 2 SD above normal for the F/S
ratio (b2.2).
Following MFCV measurements, a needle muscle biopsy
was obtained from the same muscle, and evaluated micro-
scopically by a neuropathologist according to established
principles. Muscle changes indicative of denervation were
angular atrophic fibres of both fibre types, possibly com-
bined with hypertrophic fibres with an increased number of
internal nuclei. Fibre type grouping was considered a sign of
reinnervation. Non-specific abnormalities included scattered
Table 1
Patient characteristics
Age,
sex
Symptoms at
presentation
Time from
onset to
inclusion
(months)
Follow-up
(months)
Final diagnosis
1 45, f LMN arm+
UMN leg
40 20 Definite ALS
2 64, f LMN legs 16 20 Definite ALS
3 61, m LMN bulbair,
UMN arm
30 12 Probable ALS
4 70, f LMN legs,
UMN arm
14 12 Probable ALS
5 64, f LMN+
UMN legs
11 15 Probable ALS
6 50, f LMN+
UMN leg
12 24 Probable ALS—
lab sup
7 71, m LMN leg+
UMN arm
5 12 Probable ALS
8 67, m LMN+
UMN leg
12 14 Probable ALS—
lab sup
9 66, m LMN+
UMN legs
24 12 UMN dominant ALS
10 65, m LMN legs,
ALS in family
13 17 LMN of unidentified
cause
11 75, f LMN arm 14 24 Monomelic
amyotrophy
12 60, m UMN arms
and leg
48 12 Primary lateral
sclerosis
13 50, f UMN+LMN
legs
45 15 Primary lateral
sclerosis+ inclusion
body myositis
(biopsy proven)
14 56, m LMN arm,
generalized
fasciculations
9 25 Cervical
radiculopathy
15 61, m LMN arm 24 10 Cervical
radiculopathy
16 47, m LMN both
arms,
UMN leg
75 10 Cervical myelopathy
with bilateral
amytrophic diplegia
17 51, m LMN arm 7 21 Chronic progressive
plexopathy
18 35, m LMN legs,
ALS in family
26 10 Restless legs
syndrome
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fibre hypertrophy with internal nuclei but without atrophy,
the presence of a small number of necrotic fibres, and normal
fibre diameters but other non-specific abnormal findings
such as increased subsarcolemmal mitochondrial activity.
The follow-up period was at least 1 year. During the
follow-up, patients were regularly seen by their neurologist,
until a final diagnosis of ALS, or a different disorder could
be established. The final diagnosis was based on consecutive
clinical examinations, and repeated additional investigations,
such as neuroimaging and EMG, excluding MFCV and
biopsy results.
Sensitivity, specificity, positive and negative predictive
values for a dichotomous diagnostic decision of ALS or no
ALS, were determined for MFCVand for the muscle biopsy.
A final diagnosis of ALS was defined as fulfilling the revised
El Escorial criteria for clinically probable, probable
laboratory-supported, or definite ALS.
3. Results
Eighteen patients were included: 10 with possible ALS,
and 8 with LMN signs of unidentified cause in one or two
regions. Clinical signs and symptoms, time from onset to
presentation, and follow-up period after presentation are
shown in Table 1. Eleven patients were male (mean age,
58 years; SD 10 years), and 7 female (mean age, 60 years;
SD, 11 years). Nine studies of MFCV and biopsy were
obtained from the quadriceps muscle, and 9 studies from the
brachial biceps muscle. Mean time from onset to presenta-
tion was 23 months (range: 5–75), mean follow-up period
was 16 months (range: 12–25). A final diagnosis of ALS was
established in 9 patients (2 definite ALS, 4 probable ALS, 2
probable laboratory-supported ALS, and 1 UMN-dominant
ALS). Two of these 9 patients died from ALS-related com-
plications during the follow-up period. The final diagnosis of
the patients who did not develop ALS are also shown in
Table 1. In one patient with a positive family history for
ALS, the cause of his cramps and fasciculations of the legs
remained unidentified. This patient also suffered from
restless legs syndrome.
Diagnostic accuracy of MFCV and muscle biopsy are
shown in Table 2. Abnormal MFCV was found in 8 patients
developing ALS, and in 3 patients of the non-ALS group
(2 patients with primary lateral sclerosis, and 1 patient with a
cervical radiculopathy). Denervation in the muscle biopsy
was found in 7 patients developing ALS, and non-specific
findings in the remaining 2 patients. Denervation was also
seen in 1 patient of the non-ALS group (the patient with
monomelic amyotrophy). Signs of reinnervation were found
in 2 patients, 1 of whom developed probable laboratory-
supported ALS.
Mean MFCVof the ALS group was 3.3 (SD 0.3 m/s), and
of the non-ALS group 3.4 (SD 0.6 m/s), the difference being
not significant. F/S ratio was 3.6 (SD 1.8) in the ALS group,
and 2.6 (SD 1.6) in the non-ALS group, the difference being
not significant. A specific pattern of abnormal conduction
velocities on which the ALS and non-ALS groups could be
discriminated was not found, although fibres tended to have
slower MFCV in the ALS-group (Fig. 1).
4. Discussion
This study demonstrates that increased fibre diameter
variability may indicate LMN dysfunction prior to muscle
weakness, atrophy, or nEMG abnormalities in patients who
eventually will develop ALS.
The patients included in this study represent a small but
difficult group of patients who are referred to our clinic. In
most patients, a diagnosis of ALS, or any other neurological
Table 2
Diagnostic accuracy for MFCV and muscle biopsy for the diagnosis of
probable, probable laboratory-supported, or definite ALS
Sensitivity
(%)
Specificity
(%)
Positive
predictive
value
Negative
predictive
value
MFCV 89 56 0.66 0.83
Muscle biopsy 78 89 0.88 0.80
Fig. 1. Histogram of conduction velocities of all fibres pooled of the patients of the ALS-group, the non-ALS group, and of the normal values of our laboratory
(scaled to fit). The increased conduction velocity variability is due to abnormal conduction both in the upper and the lower end.
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disorder, can usually be established after the first diagnostic
work-up. This process can be frustrated however, by normal
or inconclusive results from EMG and neuroimaging, espe-
cially if disease progression is slow. It is in these patients that
MFCV studies may prove useful. Given the high negative
predictive value, probable ALS is unlikely to develop if
MFCV is normal. In such a case, other, possibly less dev-
astating or even treatable disorders should be considered,
such as cervical myelopathy, monomelic amyotrophy, or
radiculopathy. Abnormal MFCV, when found in a clinical
and electromyographical normal muscle in a patient in whom
the diagnosis of ALS is considered, should be regarded as
evidence for a more widespread disease. In such a case, a
muscle biopsy of the same muscle may be obtained to
identify the cause of abnormal propagation velocity. If the
biopsy findings are consistent with a progressive neurogenic
disorder, the patient should be regarded as having probable
laboratory-supported ALS, and treated as such.
Slowing of propagation has been described in myopathies
as well as in neurogenic disorders [5,6,8]. The slowly con-
ducting fibres relate to atrophic fibres mainly, either due to
denervation or due to myopathy, and may also represent early
regenerating fibres. We also measured fast conducting fibres
in both groups (Fig. 1), which very likely relate to large fibres,
either due to neurogenic or (secondary) myopathic hypertro-
phy. A bimodal pattern of low and high conduction velocities,
similar as to that of diameters in neurogenic disease, was not
found. This suits the idea that the LMN disease was still in an
early stage, before extensive reinnervation had taken place.
The lack of specificity of slow or fast MFCV is a drawback of
the technique.
In this regard, morphological data can be more specific.
This was illustrated by the inflammatory signs found in the
patient with inclusion body myositis, a disorder which
should be recognized as an important mimic of ALS [10,11].
Our data confirms the notion that muscle fibre diameter
pathology needs to be rather severe before it is reflected in the
motor unit action potential, as recorded with nEMG. A
computer model that generates motor unit action potentials,
predicted that an increase of the standard deviation of mean
fibre diameter from 10 μm (which is normal) to 30 μm (which
is pathological) resulted in a significant increase only of the
number of turns and phases, but not of important parameters,
such as amplitude and duration [12]. This implicates that
nEMG is not a sensitive technique to detect changes in
muscle, if these are only light to moderate. Given the sub-
jective nature of routine nEMG investigations, it was stated
that nEMG is especially of diagnostic value if the changes are
clear-cut, the examiner experienced, or both [13].
Although the El Escorial diagnostic criteria have been
developed primarily for research purposes, good clinical
practice also requires a clear definition of the stages of a
disease. An accurate diagnosis of ALS in an early stage of
the disease is important in the context of clinical trials, as
well as for the recognition of disorders that may masquerade
as ALS. Indeed, the application of the criteria may facilitate
early recognition of non-ALS disorders in patients classified
as possible ALS [11]. Our study suggests that in those
patients in whom the normal work-up, including EMG, does
not lift the diagnosis beyond possible ALS, further studies
including MFCV and possibly muscle biopsy of an
unaffected region can be performed to search for signs of
denervation.
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